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What do I need to know about penicillin antibiotics? 
 
Penicillins belong to the beta-lactam family of antibiotics, which also includes carbapenems, 
monobactams, and cephalosporins. Penicillins are the class of antibiotics most frequently prescribed 
to children worldwide.[1] This paper summarises key principles of the pharmacology of penicillin 
antibiotics, which are clinically relevant when prescribing for children and infants.  
 
Mechanism of action  
Penicillins are bactericidal antibiotics that inhibit bacterial cell wall biosynthesis; pharmacologically, 
they target penicillin-binding proteins responsible for peptidoglycan cross-linking. Some bacteria 
display penicillin resistance; this can arise through several mechanisms, one of which involves drug 
inactivation by beta-lactamase enzymes; therefore penicillins may also be prescribed in combination 
with beta-lactamase inhibitors (BLIs) such as amoxicillin/clavulanate and piperacillin/tazobactam. The 
penicillins that are commonly prescribed for children are summarised in table 1.[2]  
 Table 1. Summary of common penicillins with examples of indications and important factors for consideration when prescribing. 
Type of penicillin Example(s) Spectrum Common indications Important factors  
Natural penicillins 
 
Benzylpenicillin sodium 
(penicillin G) 
Narrow-spectrum Early onset neonatal 
sepsis (with gentamicin) 
Penicillin G is inactivated by gastric acid, so not suitable for oral 
administration.  
(Note benzylpenicillin should be available in community settings for 
intramuscular administration in suspected meningococcal disease.) 
Suspected meningococcal 
diseases (in community 
setting) 
Phenoxymethylpenicillin 
(penicillin V) 
Streptococcal tonsillitis Suitable for streptococcal infection of mild-moderate severity. 
Unpredictable absorption (from the gastrointestinal tract), so not suitable 
for serious illnesses. Unpleasant taste. Four times daily dosing regimen 
makes compliance difficult. 
 Antistaphylococcal Flucloxacillin Penicillinase-
resistant 
Skin and soft tissue 
infections; osteomyelitis 
Narrow spectrum: targets Gram-positive pathogens particularly 
Staphylococcus aureus and Streptococcus pyogenes. Not suitable for MRSA 
(methicillin-resistant Staphylococcus aureus) infections. Poor palatability. 
Four times daily dosing affects compliance as above.  
Oxacillin 
 Aminopenicillins  
 
Amoxicillin 
 
Extended-spectrum 
 
Amoxicillin is 
recommended as first line 
treatment for community 
acquired pneumonia and 
acute (bacterial) otitis 
media. 
Semisynthetic penicillin. Amoxicillin has a similar antibacterial spectrum to 
ampicillin but equivalent oral doses result in higher plasma concentrations 
and it also has improved urinary excretion. Three times daily dosing may 
improve compliance. 
 
Ampicillin Historical treatment of 
choice for meningitis 
caused by Listeria 
monocytogenes.  
Semisynthetic, penicillin, which is closely related to amoxicillin. Ampicillin is 
now rarely used in some countries (such as the UK) because its intravenous 
formulation is very expensive, so few hospitals purchase it routinely. It 
remains widely used elsewhere, such as in the US. Four times daily dosing 
affects compliance as above. 
Combinations with beta-lactamase inhibitors (BLI) 
(Aminopenicillin) Co-amoxiclav 
(amoxicillin/clavulanic 
acid) 
Broad-spectrum Respiratory tract 
infections (if amoxicillin 
monotherapy not 
appropriate), urinary tract 
infections, animal bites  
Routinely prescribed as fixed dose combinations. Formulations suitable for 
twice daily administration are available, which is beneficial for adherence.  
Widely prescribed in emergency departments and general practice, with 
negative implications for antimicrobial resistance (AMR).   
Ureidopenicillin Piperacillin/tazobactam  Very broad  Septicaemia,  
febrile neutropaenia,  
Intravenous use only. Very broad spectrum. Increasingly prescribed in 
hospital settings for serious infections such as neutropenic sepsis. Not yet 
spectrum. 
Antipseudomonal.  
 
hospital-acquired 
pneumonia 
licensed for use in neonates, although is used off-label in some neonatal 
units.  
Carboxypenicillin  Ticarcillin/clavulanic acid Septicaemia, bacteraemia, 
intra-abdominal sepsis 
Synergistic activity with aminoglycosides against Pseudomonas. Spectrum is 
not as broad as piperacillin/tazobactam.  
 Pharmacokinetics of the penicillins in children  
This section gives an overview of penicillin pharmacokinetics (PK): absorption, distribution, 
metabolism and elimination. The PK of penicillins is affected by their hydrophilic (water-soluble) 
nature.  
(i) Absorption  
Depending on the specific type of penicillin, absorption from the gastrointestinal tract can vary (see 
table 1). Absorption of certain penicillins, such as phenoxymethylpenicillin and flucloxacillin, is 
affected by the presence of food in the stomach, so patients and their parents should be advised that 
oral doses should be taken 30 – 60 minutes before meals.  
(ii) Distribution  
The distribution of penicillins into most (non-specialist) tissues is usually excellent. In general, 
penicillin penetration of the blood-brain barrier is relatively poor (at approximately 20%) and may 
be as low as 2% in the absence of meningeal inflammation. Therefore penicillins may only be used in 
the treatment of certain types of bacterial meningitis, such as intravenous benzylpenicillin for Group 
B Streptococcal meningitis in neonates. Of note, however, piperacillin/tazobactam has particularly 
poor central nervous system (CNS) penetration and is not the treatment of choice for CNS infections. 
There is usually no clinically relevant degree of plasma protein binding of penicillins, so the majority 
of the drug is free (unbound) and therefore pharmacologically active. While there is some evidence 
that this may change in critical illness, particularly for flucloxacillin, the data are as yet insufficient to 
alter routine care.  
(iii) Metabolism 
Hepatic metabolism is of very limited significance for penicillins. Some penicillins are metabolised in 
the liver to a degree and several metabolites have been identified including penicilloic acids. The 
unchanged drug and metabolites are excreted rapidly in the urine (see below) with only small amounts 
excreted in the bile.  
(iv) Elimination  
The penicillins are hydrophilic (water-soluble) compounds, which are principally renally excreted.[3] 
These drugs have a short half-life (e.g. 1.5 to 2 hours) in children with normal renal function. 
Concentrations achieved in the urine are usually sufficient to be therapeutic and these agents are 
therefore suitable for treatment of urinary-tract infections.[2] In critical illness, the half-life of 
penicillins may be prolonged due to impaired renal function. Conversely, critical illness may also 
induce augmented renal clearance, shortening the half-life of penicillins, by enhancing their 
elimination.[4] Therefore, in such circumstances, dose frequency may need to be reviewed, typically 
after consultation with either paediatric infectious diseases, microbiology, and/or specialist pharmacy 
teams. 
 
If practising in the UK, when adjusting dose frequency (or dose) outside the recommendations of the 
British National Formulary for Children (BNFC [2]), specialist advice should be sought when possible. 
There is ongoing research into the potential role of therapeutic drug monitoring (TDM) for beta-lactam 
antibiotics in the critical care setting,[5] however this has not yet been introduced within routine 
paediatric intensive care.  
 
Issues specific to neonates 
The principal factors affecting neonatal penicillin pharmacokinetics are summarised in box 1.[3]  
Box 1. Neonatal physiological factors that influence penicillin pharmacokinetics.[3] 
 Increased body water content (~ 75% of total body weight is water vs. ~60% in adults) leads 
to increased volume of distribution and contributes to lowering circulating antibiotic 
concentrations (especially peak concentrations) in blood, requiring relatively high doses to 
treat severe infections such as meningitis. 
 Relatively lower glomerular filtration rate and renal tubular secretion cause decreased 
penicillin clearance therefore dose frequency is reduced in the first weeks of life. 
 Clearance further decreased in prematurity because of renal system immaturity, which 
prolongs penicillin half-life justifying further dose frequency reduction in preterm neonates.  
 Renal function matures significantly within first days of life, increasing drug clearance and 
decreasing half-life, which requires increased dose frequency with increasing postnatal age 
(PNA).  
 
In neonates, accurate assessment of renal function remains challenging, given the persistence of 
maternal creatinine for several days after birth: penicillin dosing regimens may warrant review if there 
is evidence of severe renal dysfunction (although dose alterations are rare in practice). There is very 
limited data regarding optimal penicillin dosing regimens in preterm neonates at varying gestational 
ages. As described in box 1, renal function matures rapidly with increasing PNA (thus decreasing 
penicillin half-life) but this is not currently reflected in most dosing guidelines, although some post-
menstrual age based dosing regimens have been published. It is advisable to seek specialist guidance 
for complex cases when necessary.  
 
  
Penicillin pharmacodynamics 
 
Efficacy  
The efficacy of penicillin antibiotics is related to the percentage of time (within each dosing interval) 
that the concentration of the unbound fraction of the drug remains above the minimum inhibitory 
concentration (MIC) of the causative pathogen, generally abbreviated to %T>MIC [6]. This concept is 
demonstrated in Figure 1 [7], together with the pharmacokinetic/pharmacodynamic (PKPD) indices 
that are important for other antibiotic classes [6].  
 
This well-established adult pharmacokinetic/pharmacodynamic (PK/PD) index, %T>MIC, is currently 
also the standard target of penicillin therapy for neonates and children. Historically, the target was to 
achieve at least 40% T>MIC during therapy, and this is sometimes elevated to 70% T>MIC (or higher) 
in critical illness. In practice, this is a difficult target to aim for, given that the majority of antimicrobial 
therapy is started empirically, in the absence of microbiologically confirmed infection. Even when 
positive cultures are obtained, it is not always possible to know the MIC of the responsible bacteria, 
and thus considering the MIC distributions of wild-type pathogen populations is important from the 
microbiological perspective. In paediatric antimicrobial therapy, empirical guidelines should consider 
the typical pathogens associated with particular conditions or infective syndromes in children, the 
likely MIC value(s), and local resistance profiles, and the principles of antimicrobial stewardship, which 
are discussed further below.[8]  
 
 
Toxicity 
Serious toxicity is rare in association with penicillin therapy. The most common adverse effect is 
antibiotic-associated diarrhoea (AAD), especially with broad-spectrum therapy such as co-amoxiclav. 
There is some evidence that different ratios of the amoxicillin to clavulanic acid components may 
affect the proportion of children who experience AAD.[9] Antimicrobial therapy can also rapidly alter 
the gut microbiome, which may contribute to AAD, although the longer-term effects are as yet 
unknown.  
Other well-known adverse reactions to penicillins include drug-induced rash and hypersensitivity. 
Penicillin allergy is commonly reported but a thorough history surrounding the possible drug allergy is 
essential, particularly in critical illness where appropriate penicillin-based therapy can be lifesaving. If 
there is a known history of penicillin-related anaphylaxis, then caution should also be exerted with the 
use of certain other beta-lactam antibiotics, namely cephalosporins (especially first- and second- 
generation e.g. cefalexin, cefaclor) and carbapenems (e.g. meropenem), as cross-reactivity in the 
allergies between these classes can occur. Figures in the literature vary widely regarding how common 
cross-reactivity is, but its importance has frequently been overstated.[10] Penicillin allergy, of some 
type, is estimated to affect 1-10% of people given penicillins[2].On detailed investigation however, the 
true incidence in patients who claim a penicillin allergy is reportedly as low as 10%.[10] In children 
likely to need recurrent penicillin-based therapy for serious illness (e.g. recurrent neutropenia in an 
oncological setting), a programme of desensitisation can be undertaken under specialist paediatric 
allergist/immunologist supervision, to overcome serious allergies.  
 
Very rarely, seizures are reported in relation to penicillin therapy, and while extremely rare, this is an 
important consideration if higher than usual doses (or dose frequencies) are prescribed. Note that 
seizures have also been reported following rapid administration of high intravenous doses, therefore 
high doses should be infused slowly, over at least thirty minutes. Electrolyte imbalances can also arise 
secondary to penicillin administration, for example as penicillin sodium salts, which can contribute to 
hypernatraemia. This can be important in critical care, especially for neonates. The sodium content 
for some common penicillins in shown below in Table 2. 
 
Table 2. Sodium content of intravenous formulation of selected injectable penicillins (based on the 
Summaries of Product Characteristics (SPCs) available on the Electronic Medicines Compendium  
https://www.medicines.org.uk/emc/ ) 
Penicillin (administered as sodium salt) Sodium (mmol) / gram penicillin 
Amoxicillin 2.60 
Ampicillin 2.73 
Benzylpenicillin  2.80 
Flucloxacillin 2.28 
Piperacillin (with tazobactam sodium) 2.36 
Ticarcillin (with potassium clavulanate) 4.37 
 
Practical prescribing 
Paediatric penicillin dosing recommendations exist in various formats including age-bands, weight-
based calculations (mg/kg), and weight-bands. There are strengths and limitations associated with 
each method of dose selection, discussed elsewhere.[11] The BNFC is the standard UK reference text 
for paediatric dosing[2] and in 2014, the dosing guidelines for oral amoxicillin and ampicillin were 
changed,[12] following concerns of widespread underdosing, especially in primary care.[13] Taking 
the specific example of amoxicillin, the standard recommended age-band doses for children were 
doubled (see Table 3).  
 Table 3. Overview of BNFC changes to recommended standard oral doses of amoxicillin for children 
aged between 1 month and 12 years from April 2014  
Age-band BNFC dose recommendations 
up to March 2014  
BNFC recommendation from April 
2014 onwards  
Child 1 month–1 year 62.5 mg 3 times daily 125 mg 3 times daily 
Child 1–5 years 125 mg 3 times daily 250 mg 3 times daily 
Child 5–18 years 250 mg 3 times daily 500 mg 3 times daily 
 
 
As new evidence from paediatric studies becomes available, dosing recommendations are thus 
regularly reviewed and updated, so it is helpful to use the online formulary resources when available, 
to access the latest evidence-based guidelines. Such changes also highlight the risks associated with 
old paperback formularies that may be kept on hospital wards, which may not reflect current dosing 
practices.  
 
When prescribing oral penicillins, adherence is a major factor contributing to therapeutic success or 
failure. To maximise the chance of adherence to the proposed regimen, it is important to have a 
careful discussion with the child (providing they are old enough to understand) and their parent/carer, 
to communicate the proposed risks and benefits of the treatment regimen, and the importance of 
completing the antibiotic course. Practical strategies such as fitting in dosing times with the daily 
routine can be very important: twice daily regimens (avoiding a dose during school) are extremely 
helpful if clinically appropriate, when a suitable formulation is available. Avoiding four-times daily oral 
antibiotics (such as flucloxacillin) also warrants consideration, when clinically justifiable. For 
adherence, palatability is another aspect that should always be at the forefront of the prescriber’s 
mind, as children are less likely to complete the course of an antibiotic which tastes unpleasant (e.g. 
flucloxacillin, and penicillin V to a lesser extent) [14]. The difficulties parents may face in measuring 
the correct dose should also be borne in mind [15] and caregivers should be given guidance regarding 
how best to administer the dose to their child in an age-appropriate fashion. Consider also the shelf-
life of the prescribed medicine when choosing a course-length and discussing the plan with the family: 
for example, the reconstituted oral solution of penicillin V has a shelf life of only seven days, meaning 
that parents would need to return to the pharmacy to collect a second bottle in order to complete a 
ten day course, which is unlikely to happen in practice.  
 
Prescribing habits to avoid 
It is important to avoid excessive or inappropriate use of extended spectrum agents such as co-
amoxiclav in emergency department and general practice settings, which has been widely recognised. 
This is partly due to the common misconception that co-amoxiclav is suitable for penicillin-resistant 
pneumococcal infections. The reasons for curbing co-amoxiclav use are manifold, but include the long-
term impact on antimicrobial resistance rates in the community, as well as possible patient-specific 
adverse effects (including AAD and effects on the microbiome in the gut and beyond, possibly 
contributing to future diseases such as obesity [16]). Whenever possible, follow the main principles of 
paediatric antimicrobial stewardship.[8]  Remember to include a review or stop date on every 
prescription to indicate the intended duration of therapy. Note, if your hospital uses electronic drug 
charts, beware that some software implements ‘stop dates’ automatically without informing the 
clinicians – so the antibiotic prescription suddenly disappears from the drug chart without requesting 
clinical review. Check whether this affects your local prescribing tool, and consider use of ‘review 
dates’ instead of ‘stop dates’ where appropriate.  
 
The future  
Although penicillins have been used for many decades in children and infants, many current paediatric 
dosing regimens were originally derived by scaling down adult dosing regimens using a linear weight-
based (mg/kg) approach, which is now known to be suboptimal.[6, 17] This was because, historically, 
it was not feasible to do large scale paediatric antibiotic studies to verify the most effective dosing 
regimens for different indications; therefore, optimal antibiotic dosing for children is currently a highly 
active research area. As paediatric antibiotic PK/PD data improve, this will allow consolidation of the 
evidence to inform and update paediatric dosage regimens in formularies and SPCs.  
 
Regarding PKPD targets of therapy, some experts now advocate aiming for 100% T>MIC by using 
continuous infusions, particularly in intensive care.[18] Given that many neonates receiving in-hospital 
antimicrobial therapy are either critically ill, or at risk of critical illness given their functional 
immunocompromise (immune system immaturity), some argue that we should also routinely aim for 
70-100% T>MIC in neonates. However, the evidence for continuous infusions is relatively sparse and 
this is another hot topic in antimicrobial research. Further, consideration must be given to the 
consequences of using continuous infusions such as (i) the potential need for additional intravenous 
access (ii) the volume required (iii) the chemical stability of the medicine itself during infusion (as 
penicillins are often unstable at room temperature), and (iv) the compatibility with other medications 
given through the same line.  
 Conclusions  
Globally, penicillins remain the most important group of antibiotics used to treat children and 
newborns. Appropriate usage is essential in the ongoing fight against antimicrobial resistance. When 
prescribing penicillins or indeed other antimicrobials for children, it is important to always apply the 
relevant principles of paediatric antimicrobial stewardship, which are summarised in box 2.  
 
Box 2. Stewardship principles pertinent to penicillin prescribing in paediatrics  
1. Use a narrow(er)-spectrum penicillin whenever possible  
2. Always set a completion or review date at the point of prescription 
3. Switch from intravenous to orally administered antibiotics as early as feasible 
4. Co-amoxiclav and other broader spectrum therapies are associated with higher rates of AAD, 
so may not be beneficial to your patient(s) 
5. Concordance is paramount: discuss this explicitly with patients and their carers  
 
Although co-amoxiclav is likely to remain popular among health professionals, remember to think 
critically before prescribing it and use amoxicillin instead unless you are specifically concerned about 
infection with amoxicillin-resistant bacteria such as Staphylococcus aureus or non-typeable 
Haemophilus influenzae. Always use the most up-to-date version of your formulary, as dosing 
recommendations do change, even for widely used antibiotics, as exemplified by amoxicillin. 
Improved paediatric penicillin PKPD data are awaited to optimize the evidence for modern dosing 
practices. In the meantime, it is recommended to follow your national formulary in conjunction with 
the relevant clinical guidelines when dosing penicillins for children, and to seek specialist advice when 
alternative dosing strategies are considered.  
 
  
Learning point box: take home messages 
 
1. Penicillins are the class of antibiotics most frequently prescribed for children worldwide and 
they remain first-line therapy for a range of infections.  
2. Penicillins are bactericidal antibiotics that inhibit bacterial cell wall biosynthesis by targeting 
penicillin binding proteins.  
3. Penicillin antibiotics can be narrow-spectrum (e.g. benzylpenicillin) or extended-spectrum 
(e.g. amoxicillin), or broad-spectrum when combined with a beta-lactamase inhibitor such as 
amoxicillin/clavulanate (co-amoxiclav). 
4. Penicillin antibiotics are principally renally excreted and the concentrations reached in the 
urine are adequate to be therapeutic for urinary-tract infections; penetration of the blood-
brain barrier is usually poor in the absence of inflammation. 
5. Always take a thorough allergy history before prescribing antibiotics, but note that serious 
drug toxicity is rare with penicillins: the most common adverse effect is antibiotic-associated 
diarrhoea (AAD). 
 
MCQs  
1. Penicillin antibiotics target:  
A. Bacterial cell wall synthesis 
B. Bacterial DNA gyrase  
C. Bacterial folic acid metabolism 
D. Bacterial protein synthesis 
 
2. Penicillin antibiotics:  
A. are mainly metabolised in the liver  
B. are mainly renally excreted 
C. can be used in the treatment of urinary tract infections  
D. penetrate well into the cerebrospinal fluid of healthy 
children  
 
3. In critical illness, the clearance of penicillin antibiotics will be:  
A. decreased because of impaired renal function 
B. increased because of augmented renal clearance  
C. A or B or neither 
D. Neither A nor B 
 
4. Penicillin allergy  
A. is commonly reported by patients or their parents 
B. is usually serious in nature 
C. is always associated with allergy to cephalosporins 
D. can be overcome with a specialist programme of 
desensitisation 
 
 
T/F 
T/F 
T/F 
T/F 
 
 
T/F 
T/F 
T/F 
T/F 
 
 
 
T/F 
T/F 
T/F 
T/F 
 
 
T/F 
T/F 
T/F 
T/F 
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 Figure legend  
Figure 1. PKPD indices of antibiotic efficacy. Cmax = maximum concentration; AUC/MIC = area under 
the curve / minimum inhibitory concentration; T>MIC = time above the MIC [7]. Reproduced under 
the terms of the Creative Commons Attribution License from Connors KP KJ, Nicolau DP. Optimizing 
Antibiotic Pharmacodynamics for Clinical Practice. Pharmaceutica Analytica Acta 2013; 4. 
 
